Literature DB >> 34203342

Betatrophin Levels Are Related to the Early Histological Findings in Nonalcoholic Fatty Liver Disease.

Alper Sonmez1, Teoman Dogru2, Cemal Nuri Ercin3, Halil Genc4, Gurkan Celebi3, Hasan Gurel5, Serkan Tapan6, Ali Fuat Cicek7, Cem Barcin8, Cem Haymana9, Ali Kirik10, Manfredi Rizzo11,12.   

Abstract

Betatrophin, a liver hormone, regulates glucose and lipid metabolism. We investigated the betatrophin levels in nonalcoholic fatty liver disease (NAFLD) and searched for any relationship with histological severity and metabolic parameters. Fifty males with NAFLD [Nonalcoholic Steatohepatitis (NASH) (n = 32); non-NASH (n = 18)] and 30 healthy controls were included. Plasma betatrophin was measured by ELISA method. Insulin sensitivity was assessed by HOMA-IR index. Histological features were scored by the semi quantitative classification and combined as the NAFLD activity score (NAS). Betatrophin levels in the non-NASH group were significantly higher than the controls. Betatrophin was positively correlated to the age, waist circumference, total cholesterol, triglycerides, LDL cholesterol, glucose, insulin, HOMA-IR index and gamma glutamyl transpeptidase levels, and negatively correlated to the steatosis and NAS. In the stepwise linear regression analysis, the triglyceride (β = 0.457, p < 0.001), glucose (β = 0.281, p = 0.02) and NAS (β = -0.260, p = 0.03) were the independent determinants of betatrophin. Betatrophin levels are higher in the early stages of NAFLD and tend to decrease when the disease progresses. This could be an important preliminary mechanistic finding to explain the increased frequency of glucose intolerance during the course of NAFLD.

Entities:  

Keywords:  betatrophin; glucose intolerance; insulin resistance; nonalcoholic fatty liver disease

Year:  2021        PMID: 34203342     DOI: 10.3390/metabo11070425

Source DB:  PubMed          Journal:  Metabolites        ISSN: 2218-1989


  27 in total

1.  Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up.

Authors:  Shira Zelber-Sagi; Roni Lotan; Oren Shibolet; Muriel Webb; Assaf Buch; Dorit Nitzan-Kaluski; Zamir Halpern; Erwin Santo; Ran Oren
Journal:  Liver Int       Date:  2013-05-08       Impact factor: 5.828

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 3.  Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications.

Authors:  Giovanni Targher; Christopher D Byrne
Journal:  J Clin Endocrinol Metab       Date:  2013-01-04       Impact factor: 5.958

4.  Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study.

Authors:  Giorgio Bedogni; Lucia Miglioli; Flora Masutti; Claudio Tiribelli; Giulio Marchesini; Stefano Bellentani
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

5.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis.

Authors:  Yan Wang; Fabiana Quagliarini; Viktoria Gusarova; Jesper Gromada; David M Valenzuela; Jonathan C Cohen; Helen H Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

7.  Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes.

Authors:  Javier Gómez-Ambrosi; Eider Pascual; Victoria Catalán; Amaia Rodríguez; Beatriz Ramírez; Camilo Silva; María J Gil; Javier Salvador; Gema Frühbeck
Journal:  J Clin Endocrinol Metab       Date:  2014-07-22       Impact factor: 5.958

8.  Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism.

Authors:  Gang Ren; Ji Young Kim; Cynthia M Smas
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-05-08       Impact factor: 4.310

Review 9.  Update on the NCEP ATP-III emerging cardiometabolic risk factors.

Authors:  Robert H Eckel; Marc-Andre Cornier
Journal:  BMC Med       Date:  2014-08-26       Impact factor: 8.775

10.  Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity.

Authors:  Zhiyao Fu; Feven Berhane; Alemu Fite; Berhane Seyoum; Abdul B Abou-Samra; Ren Zhang
Journal:  Sci Rep       Date:  2014-05-23       Impact factor: 4.379

View more
  1 in total

1.  Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory Analysis.

Authors:  Tagreed A Mazi; Kamil Borkowski; Oliver Fiehn; Christopher L Bowlus; Souvik Sarkar; Karen Matsukuma; Mohamed R Ali; Dorothy A Kieffer; Yu-Jui Y Wan; Kimber L Stanhope; Peter J Havel; John W Newman; Valentina Medici
Journal:  Metabolites       Date:  2022-02-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.